TY - JOUR T1 - Evaluation of VTE-BLEED for predicting intracranial or fatal bleedings in stable anticoagulated patients with venous thromboembolism JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00077-2018 SP - 1800077 AU - Frederikus A. Klok AU - Stefano Barco AU - Stavros V. Konstantinides Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/02/15/13993003.00077-2018.abstract N2 - Current international guidelines recommend discontinuing anticoagulant therapy for unprovoked acute pulmonary embolism (PE) or deep vein thrombosis (DVT) after the first three months of treatment only in patients considered at high risk of bleeding.1,2 The rationale for this recommendation is that unprovoked venous thromboembolism (VTE) is associated with high rates of recurrence after anticoagulant therapy quantified in up to 50% in the first 10 years.3 It remains, however, unknown how the assessment of the bleeding risk in the individual patient should be performed considering the lack of sufficiently validated risk assessment models or scores, as well as outcome trials that successfully applied those.4,5VTE-BLEED predicts fatal and/or intracranial bleedings in patients with VTE treated with long-term anticoagulantsFootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Frederikus Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, MSD and Actelion.Conflict of interest: Stefano Barco S. Barco has received congress and travel payments from Daiichi-Sankyo and financial support for the printing costs of his PhD thesis from Pfizer BV, CSL Behring bv, Sanquin Plasma Products, Boehringer Ingelheim bv, Aspen Netherlands and Bayer bv.Conflict of interest: Stavros Konstantinides reports having received consultancy and lecture honoraria from Bayer HealthCare, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer - Bristol-Myers Squibb; payment for travel accommodation/ meeting expenses from Bayer HealthCare; and institutional grants from Boehringer Ingelheim, Bayer HealthCare, and Daiichi Sankyo. ER -